BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Greg Harrison does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 KROSKeros Therapeutics Inc | Buy | $26.00 | Jun 2025 | −42.6% | Miss |
 VERAVera Therapeutics Inc | Buy | $65.00 | Jun 2025 | −10.9% | Miss |
| VERAVera Therapeutics Inc | Buy | $65.00 | Jun 2025 | −10.9% | Miss |
 LQDALiquidia Technologies Inc | Buy | $37.00 | May 2025 | +297.5% | Hit |
 RCKTRocket Pharmaceuticals Inc | Buy | $19.00 | May 2025 | −0.8% | Miss |
 ARCTArcturus Therapeutics Holdings Inc | Buy | $32.00 | May 2025 | −53.8% | Miss |
| KROSKeros Therapeutics Inc | Buy | $26.00 | May 2025 | −26.1% | Miss |
| LQDALiquidia Technologies Inc | Buy | $36.00 | May 2025 | +148.2% | Hit |
 AGIOAgios Pharm | Buy | $71.00 | May 2025 | −14.7% | Miss |
| LQDALiquidia Technologies Inc | Buy | $34.00 | Mar 2025 | +139.9% | Hit |
 BEAMBeam Therapeutics Inc | Buy | $40.00 | Mar 2025 | −8.0% | Miss |
 IRONDisc Medicine Inc. | Buy | $75.00 | Mar 2025 | +8.7% | Hit |
 GERNGeron Corporation | Buy | $4.00 | Feb 2025 | −14.0% | Miss |
| IRONDisc Medicine Inc. | Buy | $73.00 | Jan 2025 | +25.4% | Hit |
| KROSKeros Therapeutics Inc | Buy | $41.00 | Jan 2025 | +60.6% | Miss |
| KROSKeros Therapeutics Inc | Buy | $44.00 | Dec 2024 | −4.7% | Miss |
| AGIOAgios Pharm | Buy | $75.00 | Dec 2024 | −47.6% | Miss |
| AGIOAgios Pharm | Buy | $53.00 | Nov 2024 | −10.7% | Hit |
 EYPTEyepoint Pharmaceuticals Inc | Buy | $18.00 | Oct 2024 | +8.5% | Miss |
| GERNGeron Corporation | Buy | $6.00 | Oct 2024 | −64.8% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.